Showing results (301-310 of 332) with videos related to
Sort By:
Pageof 34
Leukemia|June 13, 2022
Cooperation between KDM6B overexpression and TET2 deficiency in the pathogenesis of chronic myelomonocytic leukemiaYue Wei, Rashmi Kanagal-Shamanna, Hong Zheng, et al.Cell Reports|September 8, 2021
Reshaping of the androgen-driven chromatin landscape in normal prostate cells by early cancer drivers and effect on therapeutic sensitivityIvana Grbesa, Michael A Augello, Deli Liu, et al.Signal Transduction and Targeted Therapy|May 1, 2026
Single-cell imaging analysis, therapeutic modeling and a Phase Ib trial validate BCL-2 as a target across heterogeneous castration-resistant prostate cancerAnmbreen Jamroze, Xiaozhuo Liu, Surui Hou, et al.Scientific Reports|July 21, 2018
The lincRNA MIRAT binds to IQGAP1 and modulates the MAPK pathway in NRAS mutant melanomaMartina Sanlorenzo, Igor Vujic, Rosaura Esteve-Puig, et al.Biorxiv : the Preprint Server for Biology|March 11, 2024
Canonical AREs are tumor suppressive regulatory elements in the prostateMichael A Augello, Xuanrong Chen, Deli Liu, et al.Proceedings of the National Academy of Sciences of the United States of America|March 22, 2019
Structure-guided design fine-tunes pharmacokinetics, tolerability, and antitumor profile of multispecific frizzled antibodiesSwetha Raman, Melissa Beilschmidt, Minh To, et al.Mabs|April 16, 2019
An in vitro FcRn- dependent transcytosis assay as a screening tool for predictive assessment of nonspecific clearance of antibody therapeutics in humansShan Chung, Van Nguyen, Yuwen Linda Lin, et al.Nature Communications|December 13, 2024
Canonical androgen response element motifs are tumor suppressive regulatory elements in the prostateXuanrong Chen, Michael A Augello, Deli Liu, et al.Nature Cancer|May 13, 2025
CHD1 loss reprograms SREBP2-driven cholesterol synthesis to fuel androgen-responsive growth and castration resistance in SPOP-mutated prostate tumorsFeiyu Chen, Haoyan Li, Yin Wang, et al.Cancer Research|June 30, 2022
CHD1 Promotes Sensitivity to Aurora Kinase Inhibitors by Suppressing Interaction of AURKA with Its Coactivator TPX2Haoyan Li, Yin Wang, Kevin Lin, et al.Pageof 34